In such patients, if no proper, frequent ophthalmologic assessment is possible, an anti-TNF antibody treatment, such as adalimumab, or the CTLA-4Ig abatacept may be privileged, as these biologics are most likely to prevent, to a large extent, the risk of developing uveitis. The gene discussed is TNF; the disease is uveitis.